Segantii Capital Management’s Enzo Biochem, Inc. ENZ Stock Holding History

Segantii Capital Management’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-57,864	Closed	-$256K	–	126
2016 Q1	$256K	Buy	+57,864	New	+$258K	0.11%	56

Other funds holding ENZ

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Segantii Capital Management's ENZ Position: Q2 2016 in Review

Segantii Capital Management sold out of Enzo Biochem, Inc. (ENZ) in Q2 2016, closing a stake of 57,864 shares — an estimated $256K sold.

Segantii Capital Management first reported a position in ENZ in Q1 2016 and held it in 1 quarter. The position peaked at $256K in Q1 2016. 104 funds tracked by Wall St. Rank hold ENZ as of Q2 2016.

Segantii Capital Management reported no remaining Enzo Biochem, Inc. position as of Q2 2016 after selling out during the quarter.
Segantii Capital Management sold 57,864 Enzo Biochem, Inc. shares in Q2 2016, an estimated $256K.
Segantii Capital Management first reported a position in Enzo Biochem, Inc. in Q1 2016 and held it in 1 quarter.
Segantii Capital Management's Enzo Biochem, Inc. position peaked at $256K in Q1 2016.
104 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2016.

Based on Segantii Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.